Blocking Eph–ephrin interactions with antagonistic antibodies and peptides has been explored as a potential therapeutic strategy in melanoma, breast, colon and pancreatic cancer [38,39]. This evidence concerns the gene EPHA1 and familial pancreatic carcinoma.